enfortumab,carboplatin,cisplatin,gemcitabine,pembrolizumab
seagen,merck,astellas
['mibc', 'ev-103']
ev-103: 3 cycles neoadj ev in cis-inelig pts w/ mibc (cohort h) n=22, 77.3% still on study pcr rate: 36.4% pds rate: 50.0% median efs: nr efs rate @ 12 mos: 76.4% #asco23 
Uro Onc @GACancerCenter | Assoc Prof, Resident PD, and Ronald W. Lewis, MD Chair of Uro Educ @mcg_urology | #mentalhealth research | @urotoday Contributor